Fig. 3.
Kaplan–Meier analysis for the time to prostate-specific antigen (PSA)-progression-free survival of the 55 patients who received cabazitaxel in the PSA ≥ 35 group vs the PSA < 35 group.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.